Drug testing and psychedelics: what employers can and cannot do

Last reviewed: August 29, 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Correction — August 29, 2026. An earlier edition of this article stated that Oregon law bars employers from disciplining employees solely for lawful off-duty psilocybin use, and from treating a positive drug test as proof of impairment, and attributed both rules to a statute that in fact concerns tobacco. Neither rule exists, and Oregon has no psilocybin employment statute at all. The sections below have been rewritten. The full record of this correction is in the corrections log.

For Oregon employers who want to understand what drug testing for psilocybin is legally permissible, what Oregon law restricts, and how to structure a compliant drug-free workplace policy that accounts for the state’s licensed psilocybin program.

The short answer

Oregon employers can maintain drug-free workplace policies, conduct drug testing, and take employment action based on impairment — and Oregon law constrains them far less in the psilocybin context than is commonly assumed. There is no Oregon statute protecting employees from discipline for lawful off-duty psilocybin use, and none restricting how an employer may use a positive result for a state-authorized substance. Oregon is an at-will state, and ORS chapter 475A regulates the licensed program without imposing any obligation on employers. The practical reality is that standard drug test panels do not detect psilocybin or psilocin, so most employers will never encounter a positive psilocybin result in routine testing. Where an employer is subject to federal drug-free workplace requirements, federal law governs and adds obligations the employer cannot waive. The real limits on an employer here are the ordinary ones — the anti-discrimination statutes, contractual and collective bargaining commitments, and the employer’s own written policy — not a psilocybin-specific rule.

What standard drug tests detect — and do not detect

The SAMHSA-5 panel, used in federal workplace drug testing and widely adopted by private employers, tests for: marijuana metabolites (THC-COOH), cocaine metabolites, amphetamine and methamphetamine, opiate metabolites, and phencyclidine (PCP). Psilocybin and psilocin are not included.

Extended 10-panel and 12-panel tests add benzodiazepines, barbiturates, methadone, and other substances — but still do not routinely include psilocybin or psilocin. Detecting psilocin requires a specifically targeted immunoassay or mass spectrometry assay that is not part of standard employment screening panels.

Psilocin — psilocybin’s active metabolite — is detectable in urine for approximately 8 to 24 hours after ingestion. At higher doses, detection may extend somewhat beyond that window. Hair follicle testing can theoretically capture a longer exposure history, but hair testing for psilocybin is not standard practice and analytical methods are less established than for other substances. For most employers using standard panels, a positive psilocybin result will simply not occur in routine testing regardless of whether an employee accessed Oregon’s program.

What Oregon law does and does not restrict

Oregon has no general statute regulating employer drug testing, and none addressing psilocybin. Two protections are frequently attributed to Oregon law in this context. Neither exists.

The first is a supposed prohibition on disciplining an employee solely for lawful off-duty psilocybin use. There is no such provision in Oregon law. ORS chapter 475A regulates the licensed program and the people licensed under it; it says nothing about the employment relationship, and its only employment provision — ORS 475A.489 — protects employees of psilocybin licensees who report suspected regulatory violations to the Oregon Health Authority. In an at-will state with no applicable carve-out, an employer who discharges an employee for nothing more than off-duty psilocybin access has not violated Oregon employment law. See Can I be fired for participating in a legal psilocybin program? for the full analysis.

The second is a supposed rule that a positive drug test result cannot by itself establish impairment at work. Oregon has no such statute either. As an evidentiary matter the underlying point is still sound — a positive result shows past exposure, not present impairment, and an employer who relies on a test result alone to prove impairment is on weak ground in any forum that examines the question. But that is a limit on the strength of the employer’s evidence, not a legal prohibition, and in an at-will relationship an employer does not have to prove impairment in order to act.

What employers can still do

Nothing in Oregon law limits an employer’s right to maintain a drug-free workplace or to act on actual impairment. All of the following are available to an Oregon employer.

An employer can prohibit employees from being impaired at work. If an employee reports to work showing signs of impairment — regardless of the substance — the employer can take action based on the observable impairment. Psilocybin’s acute effects last six to eight hours, and residual effects including cognitive changes, fatigue, and altered perception can persist one to two days after a full-dose session. An employer whose employee returns to work the morning after a session while still experiencing these effects has a legitimate impairment basis for action.

An employer can require employees in safety-sensitive roles to meet fitness-for-duty standards and can remove employees from safety-sensitive duties when impairment is reasonably suspected, regardless of the source of impairment.

An employer can maintain a drug-free workplace policy that reaches federally scheduled substances and can discipline employees who violate it. Because no state protection attaches to lawful off-duty psilocybin use, the employer does not need to establish that the policy rather than the use was the “actual” basis for discipline. The closest Oregon authority is Emerald Steel Fabricators, Inc. v. Bureau of Labor and Industries, 348 Or 159 (2010), in which the Oregon Supreme Court held that Oregon’s employment discrimination laws did not require an employer to accommodate an employee’s state-authorized medical marijuana use, because federal law preempted Oregon’s affirmative authorization of that use. No Oregon appellate court has applied that reasoning to psilocybin, but nothing about the licensed psilocybin program distinguishes it in the way that would matter.

Federally mandated drug-free workplace programs

Federal drug-free workplace requirements add obligations that no state law displaces, and psilocybin and psilocyn are Schedule I controlled substances under 21 U.S.C. § 812 regardless of Oregon’s authorization.

Federal contractors holding contracts above the simplified acquisition threshold (41 U.S.C. § 8102) and federal grant recipients (41 U.S.C. § 8103) must agree to provide a drug-free workplace: publish a statement prohibiting the unlawful manufacture, distribution, dispensation, possession, or use of a controlled substance in the workplace and specifying what will happen to employees who violate it, establish a drug-free awareness program, and require employees to notify the employer of any workplace drug conviction. Federal employees are covered separately by Executive Order 12564, which treats the use of illegal drugs by federal employees, on or off duty, as inconsistent with federal service. A psilocybin-positive result under a federally mandated program creates federal compliance consequences that no state law reaches.

DOT-regulated employers — airlines, trucking companies, railroads, pipelines, transit agencies, and others regulated by the FAA, FMCSA, FRA, FTA, or PHMSA — conduct safety-sensitive drug testing under 49 CFR Part 40. The federally mandated panel at 49 CFR 40.85 covers marijuana metabolites, cocaine metabolite, codeine and morphine, hydrocodone and hydromorphone, oxycodone and oxymorphone, 6-acetylmorphine, phencyclidine, amphetamine and methamphetamine, and MDMA and MDA. Psilocybin is not among them. But the framework is federal, the employer’s compliance obligations run to federal agencies, and an employee in a DOT safety-sensitive position who tests positive for anything on the federal panel faces DOT consequences that state law does not touch.

Voluntary employer drug-free workplace policies

An employer who is not subject to federal drug-free workplace requirements but maintains a voluntary drug-free workplace policy should review whether that policy is written to reach lawful off-duty psilocybin use — and if so, whether that is the employer’s actual intent.

A policy written to prohibit “use, possession, or being under the influence of illegal drugs” should be evaluated in light of Oregon’s psilocybin authorization: psilocybin use through a licensed service center is not illegal under Oregon law. A policy written to prohibit use of “federally scheduled substances” or “controlled substances under federal law” reaches psilocybin regardless of state authorization. The drafting matters for both enforcement and litigation.

Employers who want to update their policies to expressly address Oregon’s licensed psilocybin program — either to include it in prohibited conduct or to carve it out — should do so in consultation with employment counsel. The choice is a business judgment rather than a compliance requirement: Oregon law does not compel either answer, and the value of saying so expressly is that employees and supervisors both know where they stand.

Reasonable suspicion and impairment testing

Because standard drug tests do not reliably detect psilocybin and psilocin’s detection window is short, most employers who suspect psilocybin-related impairment will be working with behavioral evidence rather than test results. Oregon employers conducting reasonable-suspicion impairment assessments should document observable indicators — changes in behavior, coordination, speech, response time, or other performance markers — independent of any drug test result.

Impairment testing technologies — devices that measure cognitive performance or reaction time rather than substance metabolites — are an emerging category that some employers use alongside or instead of chemical testing. These tools assess current functional capacity rather than prior substance use, which makes them a closer evidentiary fit for the question an employer actually needs to answer and avoids the inferential gap that a metabolite result leaves open.

Employee assistance programs and self-disclosure

An employee who self-discloses psilocybin use to an employer’s EAP or HR department raises a distinct set of questions. No Oregon statute makes the disclosure itself protected, and an employer that learns of lawful off-duty use this way is not barred from acting on it. Where the disclosure also reveals an underlying medical condition, the employer is on very different ground: disability discrimination obligations attach to that information under ORS 659A.112 and its federal counterpart, and an employer that responds to the diagnosis rather than to the drug use has a discrimination problem. An employer who learns through self-disclosure that an employee’s use is creating genuine workplace fitness concerns has independent grounds for a fitness evaluation, particularly in safety-sensitive roles.

When public information may be enough

ORS chapter 475A and ORS chapter 659A are published by the Oregon Legislative Assembly and free to read. Emerald Steel Fabricators, Inc. v. Bureau of Labor and Industries, 348 Or 159 (2010), is available through CourtListener. BOLI publishes general employer guidance on Oregon employment discrimination at oregon.gov/boli; it does not publish guidance on psilocybin and employment, because Oregon has no psilocybin employment statute for it to administer. SAMHSA publishes current federal workplace drug testing guidelines at samhsa.gov. DOT testing regulations are at 49 CFR Part 40, and the federally mandated test panel is at 49 CFR 40.85. Drug-free workplace requirements for federal contractors and grant recipients are at 41 U.S.C. §§ 8102–8103.

When you should speak with a lawyer

An employer who wants to review and update their drug-free workplace policy to address Oregon’s licensed psilocybin program should consult employment counsel before making changes. An employer who has taken or is considering taking adverse employment action against an employee based on psilocybin use or a psilocybin-related test result should get legal advice before acting. An employer who is uncertain whether their federal funding or contracting status subjects them to mandatory federal drug-free workplace requirements should consult counsel to assess their specific obligations.

You might also want to read

This article is for general informational purposes only and does not constitute legal advice. Employment law, drug testing standards, and federal regulations change frequently. For advice specific to your employment situation or policy, consult a licensed attorney.